Synergistic Antimicrobial Effect of Antimicrobial Peptides CATH-1, CATH-3, and PMAP-36 With Erythromycin Against Bacterial Pathogens.

Yi Lu, Hongliang Tian, Runqiu Chen, Qian Liu, Kaixiang Jia, Dong-Liang Hu, Hongwei Chen, Chao Ye, Lianci Peng, Rendong Fang
Author Information
  1. Yi Lu: Joint International Research Laboratory of Animal Health and Animal Food Safety, College of Veterinary Medicine, Southwest University, Chongqing, China.
  2. Hongliang Tian: Joint International Research Laboratory of Animal Health and Animal Food Safety, College of Veterinary Medicine, Southwest University, Chongqing, China.
  3. Runqiu Chen: Joint International Research Laboratory of Animal Health and Animal Food Safety, College of Veterinary Medicine, Southwest University, Chongqing, China.
  4. Qian Liu: Joint International Research Laboratory of Animal Health and Animal Food Safety, College of Veterinary Medicine, Southwest University, Chongqing, China.
  5. Kaixiang Jia: Joint International Research Laboratory of Animal Health and Animal Food Safety, College of Veterinary Medicine, Southwest University, Chongqing, China.
  6. Dong-Liang Hu: Department of Zoonoses, Kitasato University School of Veterinary Medicine, Towada, Aomori, Japan.
  7. Hongwei Chen: Joint International Research Laboratory of Animal Health and Animal Food Safety, College of Veterinary Medicine, Southwest University, Chongqing, China.
  8. Chao Ye: Joint International Research Laboratory of Animal Health and Animal Food Safety, College of Veterinary Medicine, Southwest University, Chongqing, China.
  9. Lianci Peng: Joint International Research Laboratory of Animal Health and Animal Food Safety, College of Veterinary Medicine, Southwest University, Chongqing, China.
  10. Rendong Fang: Joint International Research Laboratory of Animal Health and Animal Food Safety, College of Veterinary Medicine, Southwest University, Chongqing, China.

Abstract

With the increasing bacterial resistance to traditional antibiotics, there is an urgent need for the development of alternative drugs or adjuvants of antibiotics to enhance antibacterial efficiency. The combination of antimicrobial peptides (AMPs) and traditional antibiotics is a potential alternative to enhance antibacterial efficiency. In this study, we investigated the synergistic bactericidal effect of AMPs, including chicken (CATH-1,-2,-3, and -B1), mice (CRAMP), and porcine (PMAP-36 and PR-39) in combination with conventional antibiotics containing ampicillin, tetracycline, gentamicin, and erythromycin against , and . The results showed that the minimum bactericidal concentration (MBC) of CATH-1,-3 and PMAP-36 was lower than 10 μM, indicating that these three AMPs had good bacterial activity against , and . Then, the synergistic antibacterial activity of AMPs and antibiotics combination was determined by the fractional bactericidal concentration index (FBCI). The results showed that the FBCI of AMPs (CATH-1,-3 and PMAP-36) and erythromycin was lower than 0.5 against bacterial pathogens, demonstrating that they had a synergistic bactericidal effect. Furthermore, the time-killing kinetics of AMPs (CATH-1,-3 and PMAP-36) in combination with erythromycin showed that they had a continuous killing effect on bacteria within 3 h. Notably, the combination showed lower hemolytic activity and cytotoxicity to mammal cells compared to erythromycin and peptide alone treatment. In addition, the antibacterial mechanism of CATH-1 and erythromycin combination against was studied. The results of the scanning electron microscope showed that CATH-1 enhanced the antibacterial activity of erythromycin by increasing the permeability of bacterial cell membrane. Moreover, the results of bacterial migration movement showed that the combination of CATH-1 and erythromycin significantly inhibits the migration of . Finally, drug resistance analysis was performed and the results showed that CATH-1 delayed the emergence of resistance to erythromycin. In conclusion, the combination of CATH-1 and erythromycin has synergistic antibacterial activity and reduces the emergence of bacterial drug resistance. Our study provides valuable information to develop AMPs as potential substitutes or adjuvants for traditional antibiotics.

Keywords

References

  1. Nat Protoc. 2008;3(2):163-75 [PMID: 18274517]
  2. Prog Lipid Res. 2012 Apr;51(2):149-77 [PMID: 22245454]
  3. J Innate Immun. 2012;4(4):361-70 [PMID: 22739631]
  4. Antimicrob Agents Chemother. 2010 May;54(5):1693-9 [PMID: 20176897]
  5. BMC Microbiol. 2019 Mar 8;19(1):54 [PMID: 30849936]
  6. Int J Mol Sci. 2021 Oct 16;22(20): [PMID: 34681833]
  7. FEMS Microbiol Rev. 2016 Jul 1;40(4):437-463 [PMID: 28201713]
  8. Microbiology (Reading). 2018 Nov;164(11):1327-1344 [PMID: 30136920]
  9. Drug Des Devel Ther. 2017 Mar 22;11:939-946 [PMID: 28356719]
  10. Vet Microbiol. 2016 Oct 15;194:107-111 [PMID: 26453316]
  11. Antibiotics (Basel). 2015 Aug 24;4(3):358-78 [PMID: 27025629]
  12. Lancet. 2022 Feb 12;399(10325):629-655 [PMID: 35065702]
  13. Eur J Med Chem. 2017 Aug 18;136:428-441 [PMID: 28525841]
  14. Clin Microbiol Rev. 2006 Jul;19(3):491-511 [PMID: 16847082]
  15. Int J Pharm. 2017 Jun 30;526(1-2):244-253 [PMID: 28461263]
  16. Biomaterials. 2014 Feb;35(6):2032-8 [PMID: 24314557]
  17. Antimicrob Agents Chemother. 2020 Dec 16;65(1): [PMID: 33020156]
  18. Sci Rep. 2016 Sep 14;6:32948 [PMID: 27624595]
  19. PLoS One. 2014 Apr 22;9(4):e95939 [PMID: 24755622]
  20. PLoS One. 2014 Jan 21;9(1):e86364 [PMID: 24466055]
  21. Microb Pathog. 2019 Nov;136:103712 [PMID: 31491551]
  22. Sci Rep. 2021 Jan 22;11(1):2132 [PMID: 33483611]
  23. PLoS One. 2013 Apr 22;8(4):e61964 [PMID: 23613986]
  24. Dev Comp Immunol. 2022 Jun;131:104377 [PMID: 35189160]
  25. mSphere. 2017 Nov 1;2(6): [PMID: 29104934]
  26. Front Cell Infect Microbiol. 2019 Apr 30;9:128 [PMID: 31114762]
  27. Nat Microbiol. 2020 Aug;5(8):1040-1050 [PMID: 32424338]
  28. Antimicrob Resist Infect Control. 2019 Nov 4;8:170 [PMID: 31709047]
  29. PLoS One. 2012;7(10):e46476 [PMID: 23077510]
  30. Nat Rev Drug Discov. 2020 May;19(5):311-332 [PMID: 32107480]
  31. Curr Top Microbiol Immunol. 2016;398:3-33 [PMID: 27406189]
  32. Front Cell Infect Microbiol. 2019 Feb 26;9:48 [PMID: 30863725]
  33. Front Cell Infect Microbiol. 2020 Oct 23;10:572849 [PMID: 33194811]
  34. FEMS Microbiol Rev. 2017 May 1;41(3):430-449 [PMID: 28419231]
  35. Int J Mol Sci. 2016 Jun 30;17(7): [PMID: 27376281]
  36. Cell Mol Life Sci. 2021 May;78(9):4259-4282 [PMID: 33595669]
  37. Antimicrob Agents Chemother. 2019 Jun 24;63(7): [PMID: 30988150]

Word Cloud

Created with Highcharts 10.0.0CATH-1erythromycinantibacterialcombinationantibioticsAMPsshowedbacterialactivityresistancesynergisticPMAP-36resultstraditionalbactericidal-3effectlowerincreasingalternativeadjuvantsenhanceefficiencyantimicrobialpeptidespotentialstudyconcentrationFBCImechanismmigrationdrugemergenceAntimicrobialurgentneeddevelopmentdrugsinvestigatedincludingchicken-2-B1miceCRAMPporcinePR-39conventionalcontainingampicillintetracyclinegentamicinminimumMBC10μMindicatingthreegooddeterminedfractionalindex05pathogensdemonstratingFurthermoretime-killingkineticscontinuouskillingbacteriawithin3hNotablyhemolyticcytotoxicitymammalcellscomparedpeptidealonetreatmentadditionstudiedscanningelectronmicroscopeenhancedpermeabilitycellmembraneMoreovermovementsignificantlyinhibitsFinallyanalysisperformeddelayedconclusionreducesprovidesvaluableinformationdevelopsubstitutesSynergisticEffectPeptidesCATH-3ErythromycinBacterialPathogensantibiotic

Similar Articles

Cited By